Per Svenningsson

Per Svenningsson is a neurologist specializing in the neuropharmacology of movement disorders such as Parkinson's disease. He is a professor of neurology at the Department of Clinical Neuroscience at the Karolinska Institutet and in the Department of Neurology at Karolinska University Hospital in Stockholm, Sweden. He is the team leader of a research group that studies the underlying pathogenic process of PD. Svenningsson is also a member of many research councils and committee, including the European College of Neuropsychopharmacology (ECNP, 2013-2016). Provided by Wikipedia
Showing 1 - 20 results of 62 for search 'Per Svenningsson', query time: 0.06s Refine Results
  1. 1
    Editorial: Body fluid biomarkers in neurodegenerative studies: Novel insights into pathophysiology to support clinical practice and drug development

    Editorial: Body fluid biomarkers in neurodegenerative studies: Novel insights into pathophysiology to support clinical practice and drug development by Anastasia Bougea, Per Svenningsson, Per Svenningsson, Ioanna Markaki, Ioanna Markaki, Abdul Hye, Stefania Mondello

    Published 2023-01-01
    Get full text
    Article
  2. 2
    Pupil light reflex dynamics in Parkinson’s disease

    Pupil light reflex dynamics in Parkinson’s disease by Panagiota Tsitsi, Panagiota Tsitsi, Mattias Nilsson, Josefine Waldthaler, Josefine Waldthaler, Gustaf Öqvist Seimyr, Olof Larsson, Per Svenningsson, Per Svenningsson, Per Svenningsson, Ioanna Markaki, Ioanna Markaki

    Published 2023-08-01
    Get full text
    Article
  3. 3
    Violin playing with flow and improved neurological findings in (atypical) Parkinson’s disease

    Violin playing with flow and improved neurological findings in (atypical) Parkinson’s disease by Töres Theorell, Fredrik Ullén, Per Svenningsson

    Published 2022-08-01
    Get full text
    Article
  4. 4
    Paroxysmal Kinesigenic Dyskinesia

    Paroxysmal Kinesigenic Dyskinesia by Martin Paucar, Helena Malmgren, Per Svenningsson

    Published 2017-12-01
    Get full text
    Article
  5. 5
    Pathological Study of a FMR1 Premutation Carrier With Progressive Supranuclear Palsy

    Pathological Study of a FMR1 Premutation Carrier With Progressive Supranuclear Palsy by Martin Paucar, Inger Nennesmo, Per Svenningsson

    Published 2018-08-01
    Get full text
    Article
  6. 6
    Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson’s Disease with Comorbid Depression versus Patients with Major Depressive Disorder

    Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson’s Disease with Comorbid Depression versus Patients with Major Depressive Disorder by Per Svenningsson, Sven Pålhagen, Aleksander A. Mathé

    Published 2017-06-01
    Get full text
    Article
  7. 7
    α-Synuclein induced cholesterol lowering increases tonic and reduces depolarization-evoked synaptic vesicle recycling and glutamate release

    α-Synuclein induced cholesterol lowering increases tonic and reduces depolarization-evoked synaptic vesicle recycling and glutamate release by Vesna Lazarevic, Yunting Yang, Wojciech Paslawski, Per Svenningsson

    Published 2022-06-01
    Get full text
    Article
  8. 8
    Are ATXN2 variants modifying our understanding about neural pathogenesis, phenotypes, and diagnostic?

    Are ATXN2 variants modifying our understanding about neural pathogenesis, phenotypes, and diagnostic? by Jose Miguel Laffita-Mesa, Martin Paucar, Per Svenningsson

    Published 2022-01-01
    Get full text
    Article
  9. 9
    Internet-based cognitive behavioral therapy for depression and anxiety in Parkinson's disease — A pilot study

    Internet-based cognitive behavioral therapy for depression and anxiety in Parkinson's disease — A pilot study by Martin Kraepelien, Per Svenningsson, Nils Lindefors, Viktor Kaldo

    Published 2015-03-01
    Get full text
    Article
  10. 10
    Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease

    Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease by Panagiota Tsitsi, Ioanna Markaki, Josefine Waldthaler, Maciej Machaczka, Per Svenningsson

    Published 2022-01-01
    Get full text
    Article
  11. 11
    Impaired migratory phenotype of CD4+ T cells in Parkinson’s disease

    Impaired migratory phenotype of CD4+ T cells in Parkinson’s disease by Dejan Mamula, Shervin Khosousi, Yachao He, Vesna Lazarevic, Per Svenningsson

    Published 2022-12-01
    Get full text
    Article
  12. 12
    The leukotriene receptor antagonist montelukast as a potential therapeutic adjuvant in multiple sclerosis – a review

    The leukotriene receptor antagonist montelukast as a potential therapeutic adjuvant in multiple sclerosis – a review by Frank Pietrantonio, Alex Serreqi, Horst Zerbe, Per Svenningsson, Ludwig Aigner

    Published 2024-09-01
    Get full text
    Article
  13. 13
    Sex Differences in the Allele Distribution of PGLYRP2 Variant rs892145 in Parkinson’s Disease

    Sex Differences in the Allele Distribution of PGLYRP2 Variant rs892145 in Parkinson’s Disease by Caroline Ran, Karin Wirdefeldt, Olof Sydow, Per Svenningsson, Rochellys Diaz Heijtz

    Published 2023-01-01
    Get full text
    Article
  14. 14
    A non-invasive olfactory bulb measure dissociates Parkinson’s patients from healthy controls and discloses disease duration

    A non-invasive olfactory bulb measure dissociates Parkinson’s patients from healthy controls and discloses disease duration by Behzad Iravani, Artin Arshamian, Martin Schaefer, Per Svenningsson, Johan N. Lundström

    Published 2021-08-01
    Get full text
    Article
  15. 15
    Cortex-wide topography of 1/f-exponent in Parkinson’s disease

    Cortex-wide topography of 1/f-exponent in Parkinson’s disease by Pascal Helson, Daniel Lundqvist, Per Svenningsson, Mikkel C. Vinding, Arvind Kumar

    Published 2023-07-01
    Get full text
    Article
  16. 16
    Tau Isoform-Driven CBD Pathology Transmission in Oligodendrocytes in Humanized Tau Mice

    Tau Isoform-Driven CBD Pathology Transmission in Oligodendrocytes in Humanized Tau Mice by Justyna Zareba-Paslawska, Kalicharan Patra, Luca Kluzer, Tamas Revesz, Per Svenningsson

    Published 2021-01-01
    Get full text
    Article
  17. 17
    Saccadic Impairments in Patients with the Norrbottnian Form of Gaucher’s Disease Type 3

    Saccadic Impairments in Patients with the Norrbottnian Form of Gaucher’s Disease Type 3 by Josefine Blume, Stanislav Beniaminov, Cecilia Kämpe Björkvall, Maciej Machaczka, Per Svenningsson

    Published 2017-06-01
    Get full text
    Article
  18. 18
    [18F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study

    [18F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study by Vera S. Kerstens, Patrik Fazio, Mathias Sundgren, Christer Halldin, Per Svenningsson, Andrea Varrone

    Published 2023-04-01
    Get full text
    Article
  19. 19
    Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease

    Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease by Wojciech Paslawski, Shervin Khosousi, Ellen Hertz, Ioanna Markaki, Adam Boxer, Per Svenningsson

    Published 2023-09-01
    Get full text
    Article
  20. 20
    GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson’s Disease Patients

    GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson’s Disease Patients by Jean-Ha Baek, Dejan Mamula, Beata Tingstam, Marcela Pereira, Yachao He, Per Svenningsson

    Published 2019-07-01
    Get full text
    Article

Search Tools: